Get-up and Go: Adynamic Bone Disease in Chronic Kidney Disease Patient

被引:0
|
作者
Magbri, Awad [1 ]
El-Magbri, Mariam [1 ]
Hernandez, Pablo Abrego [1 ]
机构
[1] Marshfield Clin Fdn Med Res & Educ, Weston, WI 54449 USA
关键词
Adynamic bone disease; Secondary hyperparathyroidism; Chronic kidney disease; Vitamin D analogs; Hypercalcemia; Peritoneal dialysis; STAGE RENAL-FAILURE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; ALKALINE-PHOSPHATASE; CALCIUM-CARBONATE; MINERAL DENSITY; OSTEODYSTROPHY; TURNOVER; FRACTURES; TERIPARATIDE;
D O I
10.51847/suXosREK5t
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We reported a case of adynamic bone disease (ABD) in an older woman with chronic kidney disease, stage-4 (CKD-4), with an estimate of 29ml/min glomerular filtration rate (eGFR). Similarly, the patient presented with bone pain and osteoporosis as well as intact parathyroid hormone (PTH) was suppressed (<6ng/dl) secondary to the use of vitamin D analogs for secondary hyperparathyroidism (SHPT) of CKD. Furthermore, the hypercalcemia of (11.1 mg/dl), and her dual-energy X-ray absorptiometry (DEXA) scan showed bone mineral density (BMD) of-2.6 SD. Low levels of PTH induces a state of low turnover bone disease. Numerous, factors are involved in this process in patients with ESRD on dialysis. Among these factors are the use of vitamin D analogs, the ill-effects high calcium baths, treatment of osteoporosis with bisphosphonates, etc. All these factors can singly or in combination suppress PTH and render the bone resistant to its action with the end results of a dynamic bone disease. The vitamin D analogs were stopped to allow recovery of the PTH and activation of the osteocytes and osteoblasts. Six months after stopping active vitamin D analogs, her hypercalcemia was resolved, and the PTH increased to 172 ng/dl. Her bone pain has resolved.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [41] Patient education for phosphorus management in chronic kidney disease
    Kalantar-Zadeh, Kamyar
    PATIENT PREFERENCE AND ADHERENCE, 2013, 7 : 379 - 390
  • [42] Imaging in Chronic Kidney Disease-Metabolic Bone Disease
    Alexander, Anup J.
    Jahangir, David
    Lazarus, Martin
    Sprague, Stuart M.
    SEMINARS IN DIALYSIS, 2017, 30 (04) : 361 - 368
  • [43] Advances in renal bone disease: Osteoporosis and chronic kidney disease
    Sprague S.M.
    Barnato S.
    Current Rheumatology Reports, 2009, 11 (3) : 185 - 190
  • [44] Development and Validation of a Uremic Pruritus Treatment Algorithm and Patient Information Toolkit in Patients With Chronic Kidney Disease and End Stage Kidney Disease
    Ragazzo, Jessica
    Cesta, Annemarie
    Jassal, S. Vanita
    Chiang, Nicholas
    Battistella, Marisa
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2020, 59 (02) : 279 - +
  • [45] Relative hypoparathyroidism and adynamic bone disease
    Mucsi, I
    Hercz, G
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 317 (06) : 405 - 409
  • [46] The consequences of chronic kidney disease on bone metabolism and growth in children
    Bacchetta, Justine
    Harambat, Jerome
    Cochat, Pierre
    Salusky, Isidro B.
    Wesseling-Perry, Katherine
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (08) : 3063 - 3071
  • [47] Bone mass measurements in men and women with chronic kidney disease
    Jamal, Sophie A.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (04) : 343 - 348
  • [48] Prevalence of Mineral Bone Disease in Chronic Kidney Disease Patients using Biochemical Markers
    Choudhary, Reeta
    Yadav, Charu
    Jain, Pallavi
    Bansal, Shyam Bihari
    Bansal, Beena
    Harith, Arun Kumar
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2020, 14 (08)
  • [49] Reversal of adynamic bone disease by lowering of dialysate calcium
    Haris, A.
    Sherrard, D. J.
    Hercz, G.
    KIDNEY INTERNATIONAL, 2006, 70 (05) : 931 - 937
  • [50] A new approach for evaluating bone turnover in chronic kidney disease
    Tolouian, Ramin
    Hernandez, German T.
    Chiang, Wen-Yuan
    Gupta, Ajay
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2010, 21 (03) : 230 - 232